Atypical venous thromboses in myeloproliferative neoplasias

Summary

We describe two patients who developed an extensive catheter-related upper extremity deep vein thrombosis and a cerebral venous sinus thrombosis, respectively. Both thrombotic complications occurred in the presence of an elevated platelet count. Subsequent detection of the JAK2 V617F and MPL mutations led to the diagnosis of a myeloproliferative neoplasia.

Zusammenfassung

Wir berichten über zwei Patienten, die eine ausgedehnte Katheter-assoziierte tiefe Venenthrombose der oberen Extremität bzw. eine intrakranielle Sinusthrombose entwickelten. In beiden Fällen war zum Zeitpunkt der Thrombose eine erhöhte Thrombozytenzahl auffällig. Der Nachweis einer JAK2 V617F-Mutation im ersten und einer MPL-Mutation im zweiten Fall führte zur Diagnose einer myeloproliferativen Neoplasie.

Keywords

Catheter-related upper extremity deep vein thrombosis - cerebral venous sinus thrombosis - thrombocytosis - JAK2 V617F mutation - MPL mutation - myeloproliferative neoplasias - essential thrombocythemia - polycythemia vera

Schlüsselwörter

Katheter-assoziierte tiefe Venenthrombose der oberen Extremität - Sinusthrombose - JAK2 V617F-Mutation - MPL-Mutation - myeloproliferative Neoplasien - essenzielle Thrombo -zythämie - Polycythaemia vera

• References

• 1 Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters – a review. J Thromb Haemost 2005; 3 (Suppl. 11) 2409-2419.
• 2 Buss DH, Cashell AW, O’Connor ML, Richards 2nd F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96 (Suppl. 03) 247-253.
• 3 Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110 (Suppl. 04) 1092-1097.
• 4 Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24 (Suppl. 06) 1128-1138.
• 5 Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28 (Suppl. 07) 1407-1413.
• 6 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90 (Suppl. 02) 162-73.
• 7 Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E. et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115 (Suppl. 04) 778-782.
• 8 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33 (Suppl. 04) 313-320.
• 9 Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev 2010; 24 (Suppl. 06) 227-232.
• 10 Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost 2010; 103 (Suppl. 06) 1136-1144.
• 11 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120 (Suppl. 25) 4921-4928.
• 12 Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A. et al. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study. Am J Hematol 2014; 89 (Suppl. 11) E200-205.
• 13 Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G. et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 2008; 111 (Suppl. 02) 666-671.
• 14 Adams BD, Baker R, Lopez JA, Spencer S. Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 2010; 24 (Suppl. 03) 585-602.
• 15 Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G. et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 2011; 118 (Suppl. 09) 2599-2601.
• 16 Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Finazzi G. et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 2011; 86 (Suppl. 04) 337-342.
• 17 Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13 (Suppl. 01) 34-39.
• 18 Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T. et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112 (Suppl. 10) 4061-4068.
• 19 Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A. et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94 (Suppl. 07) 911-918.
• 20 van Genderen PJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl. 01) 79-82.
• 21 Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P. et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6 (Suppl. 04) 569-576.
• 22 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (Suppl. 13) 2176-2184.
• 23 Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (Suppl. 26) 5128-5133 quiz 252.
• 24 Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014; 124 (Suppl. 19) 3021-3023.
• 25 Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I. et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71 (Suppl. 01) 1-6.
• 26 Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (Suppl. 22) 5857-5859.
• 27 Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. American College of Chest Physicians Antithrombotic T. et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) 7S-47S.
• 28 Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE. et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 2014; 93 (Suppl. 12) 1953-1963.
• 29 Hernandez-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larran A, Gomez M, Barba P. et al. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 2015; 94 (Suppl. 06) 911-918.